Last reviewed · How we verify
PHENOXYBENZAMINE HYDROCHLORIDE
Phenoxybenzamine Hydrochloride is a marketed drug primarily indicated for the treatment of pheochromocytoma. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market position. The primary risk is the potential increase in competition following patent expiry in 2028.
At a glance
| Generic name | PHENOXYBENZAMINE HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1953 |
Approved indications
- Pheochromocytoma
Common side effects
- Postural hypotension
- Tachycardia
- Inhibition of ejaculation
- Nasal congestion
- Miosis
- Gastrointestinal irritation
- Drowsiness
- Fatigue
Drug interactions
- epinephrine
- levarterenol
- reserpine
Key clinical trials
- Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks (PHASE4)
- The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma (PHASE4)
- Phenoxybenzamine Versus Doxazosin in PCC Patients (PHASE4)
- Preoperative Alpha Blockade for Pheochromocytoma (PHASE3)
- Selective Versus Nonselective Alpha-blockade Prior to Pheochromocytoma Resection - Systematic Review and Meta-analysis
- Pheochromocytoma and Hemodynamic Instability
- Use of Phenoxybenzamine [PBZ] IV to Assist High Flow Low Pressure Perfusion [HFLPP] on Cardio-pulmonary Bypass (NA)
- Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PHENOXYBENZAMINE HYDROCHLORIDE CI brief — competitive landscape report
- PHENOXYBENZAMINE HYDROCHLORIDE updates RSS · CI watch RSS